Correction: Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma

Abstract

Correction for ‘Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma’ by M. A. Rajora et al., Chem. Sci., 2017, DOI: ; 10.1039/c7sc00732a.

In Fig. 6 of the paper, the labels for the final two sets of treatment groups should be switched around as indicated in the revised figure.

Fig. 6. In vitro evaluation of pyE-LN PDT sensitization. Cell viability was normalized to untreated cells and is presented as the average of three replicates ± standard deviation. Cells were treated with py-LN-CO (3 μM), laser (671 nm) or a combination of laser and particle. Significant differences (*p < 0.01, n = 3) were observed between treated and untreated cells, wherein significantly higher toxicity (**p < 0.01, n = 3) was observed in U87 cells versus ldlA7 cells treated with particle and laser.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.